Web Exclusive. Annals for Hospitalists Inpatient Notes - Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction-What Hospitalists Need to Know.

Abstract

Web ExclusivesApril 2023Annals for Hospitalists Inpatient Notes - Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction—What Hospitalists Need to KnowSarah K. Adie, PharmD, and Matthew C. Konerman, MDSarah K. Adie, PharmDDepartment of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan (S.K.A.)Search for more papers by this author, and Matthew C. Konerman, MDDepartment of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan (M.C.K.).Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-0588 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Sodium–glucose cotransporter-2 inhibitors (SGLT2Is) improve outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease, and heart failure (HF) with reduced ejection fraction (1). They also benefit patients with heart failure with preserved ejection fraction (HFpEF), a population often managed by hospitalists.Evidence for SGLT2Is in HFpEFThe DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial randomly assigned 6263 patients with HF and left ventricular ejection fraction greater than 40% to receive either 10 mg of dapagliflozin daily or placebo (1). Less than half of the patients had T2DM. The composite of ...